Perry Premdas Net Worth

The estimated Net Worth of Perry W Premdas is at least $2.47 Milión dollars as of 10 November 2008. Mr. Premdas owns over 6,700 units of Balchem stock worth over $2,287,382 and over the last 20 years he sold BCPC stock worth over $0. In addition, he makes $186,836 as Independent Director at Balchem.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Premdas BCPC stock SEC Form 4 insiders trading

Perry has made over 2 trades of the Balchem stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 6,700 units of BCPC stock worth $160,733 on 10 November 2008.

The largest trade he's ever made was buying 6,700 units of Balchem stock on 10 November 2008 worth over $160,733. On average, Perry trades about 91 units every 2 days since 2005. As of 10 November 2008 he still owns at least 13,950 units of Balchem stock.

You can see the complete history of Mr. Premdas stock trades at the bottom of the page.

Perry Premdas biography

Perry W. Premdas serves as Independent Director of the Company. Mr. Premdas was Chief Financial Officer of Celanese AG, a chemical and plastics business spun-off by Hoechst AG and listed on the Frankfurt stock exchange and the NYSE from 1999 to 2004. Senior Executive Vice President and Chief Financial Officer of Centeon LLC from 1997 to 1998.

What is the salary of Perry Premdas?

As the Independent Director of Balchem, the total compensation of Perry Premdas at Balchem is $186,836. There are 12 executives at Balchem getting paid more, with Theodore Harris having the highest compensation of $3,808,410.

How old is Perry Premdas?

Perry Premdas is 67, he's been the Independent Director of Balchem since 2017. There are no older and 11 younger executives at Balchem.

What's Perry Premdas's mailing address?

Perry's mailing address filed with the SEC is C/O BALCHEM CORPORATION, 5 PARAGON DRIVE, MONTVALE, NJ, 07645.

Insiders trading at Balchem

Over the last 22 years, insiders at Balchem have traded over $37,143,279 worth of Balchem stock and bought 47,350 units worth $1,702,145 . The most active insiders traders include Dino A Rossi, Frank Fitzpatrick a David F Ludwig. On average, Balchem executives and independent directors trade stock every 36 days with the average trade being worth of $2,396,094. The most recent stock trade was executed by Gunsteren Job Leonard Van on 31 July 2024, trading 7,750 units of BCPC stock currently worth $462,288.

What does Balchem do?

founded in 1967, balchem provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. our company consists of four business segments: human nutrition & health; specialty products; animal nutrition and health and industrial products. balchem employs approximately 1,000 people worldwide who are engaged in many diverse activities, developing our company into chosen market leadership positions. visit our website at www.balchem.com to learn more about us and the exciting opportunities we have available!

Complete history of Mr. Premdas stock trades at Balchem, Compass Minerals International Inc a Ferro

Balchem executives and stock owners

Balchem executives and other stock owners filed with the SEC include:

• Theodore Harris,
  Chairman of the Board, President, Chief Executive Officer
• Theodore L. Harris,
  Chairman, CEO & Pres
• Martin Bengtsson,
  Chief Financial Officer
• Scott Mason,
  Vice President of Manufacturing and Supply Chain and Vice President and General Manager, Industrial Products
• William Backus,
  Chief Accounting Officer
• Mark Stach,
  General Counsel, Secretary
• Carl Martin Bengtsson,
  CFO & Treasurer
• James C. Hyde,
  Sr. VP and GM of Human Nutrition & Health
• Mark A. Stach,
  Gen. Counsel & Corp. Sec.
• John Televantos,
  Lead Independent Director
• Daniel Knutson,
  Independent Director
• Matthew Wineinger,
  Independent Director
• Perry Premdas,
  Independent Director
• David Fischer,
  Independent Director
• Paul Coombs,
  Independent Director
• Joyce Lee,
  Independent Director
• Dino A Rossi,
  President and CEO
• Edward Mcmillan,
  Director
• Matthew David Houston,
  General Counsel, Secretary
• Frank Fitzpatrick,
  Corp Controller & Treasurer
• Mary Theresa Coelho,
  Chief Financial Officer
• Monica Vicente,
  
• Olivier Rigaud,
  
• Elaine R Wedral,
  Director
• Richard Allen Bendure,
  Chief Operating Officer
• Francis X Mcdermott,
  Director
• Paul H Richardson,
  VP Research and Development
• Dana E. Putnam,
  VP and General Manager
• Cruce Patricia Siuta,
  Vice President Technology
• Israel Sheinberg,
  Director
• Winston A Samuels,
  Vice President/GM Encapsulates
• Hoyt Jr Ammidon,
  Director
• Kenneth P Mitchell,
  Director
• Robert T Miniger,
  VP/Human Resources
• David F Ludwig,
  Vice President
• James C Hyde,
  Sr. Vice President
• Kathleen B Fish,
  
• Frederic Boned,
  SVP/GM, Human Nutri. & Health
• Martin Luther Reid,
  SVP Chief Supply Chain Officer
• Hatsuki Miyata,
  EVP, Gen. Counsel & Secretary
• Gunsteren Job Leonard Van,
  SVP and GM, Specialty Products
• Michael Robert Sestrick,
  SVP & Chief Technology Officer
• Michael Brent Tignor,
  SVP & Chief HR Officer
• Jonathan Harrison Griffin,
  SVP & GM, Animal Nutrition